Aerospace & Defense
Build Your Comparison
Side-by-side financial analysisStock Comparison
RAL vs DHR vs KO vs HON vs EMR
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
Beverages - Non-Alcoholic
Conglomerates
Industrial - Machinery
RAL vs DHR vs KO vs HON vs EMR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Aerospace & Defense | Medical - Diagnostics & Research | Beverages - Non-Alcoholic | Conglomerates | Industrial - Machinery |
| Market Cap | $7.40B | $127.47B | $355.61B | $139.60B | $80.13B |
| Revenue (TTM) | $2.12B | $24.78B | $49.28B | $36.76B | $18.32B |
| Net Income (TTM) | $-1.24B | $3.69B | $13.70B | $4.10B | $2.44B |
| Gross Margin | 46.2% | 60.7% | 61.7% | 36.9% | 52.7% |
| Operating Margin | 11.9% | 21.0% | 29.3% | 14.9% | 19.8% |
| Forward P/E | 24.9x | 21.3x | 25.3x | 21.0x | 22.0x |
| Total Debt | $1.15B | $18.42B | $45.49B | $34.58B | $13.76B |
| Cash & Equiv. | $319M | $4.62B | $10.27B | $12.49B | $1.54B |
RAL vs DHR vs KO vs HON vs EMR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 25 | Jun 26 | Return |
|---|---|---|---|
| Ralliant Corp. (RAL) | 100 | 136.3 | +36.3% |
| Danaher Corporation (DHR) | 100 | 91.2 | -8.8% |
| The Coca-Cola Compa… (KO) | 100 | 116.8 | +16.8% |
| Honeywell Internati… (HON) | 100 | 94.6 | -5.4% |
| Emerson Electric Co. (EMR) | 100 | 107.3 | +7.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RAL vs DHR vs KO vs HON vs EMR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
RAL is the #2 pick in this set and the best alternative if momentum is your priority.
- +39.5% vs DHR's -11.5%
DHR ranks third and is worth considering specifically for sleep-well-at-night and defensive.
- Lower volatility, beta 0.70, Low D/E 35.1%, current ratio 1.87x
- Beta 0.70, yield 0.7%, current ratio 1.87x
- Beta 0.70 vs RAL's 1.69, lower leverage
KO carries the broadest edge in this set and is the clearest fit for income & stability and valuation efficiency.
- Dividend streak 56 yrs, beta -0.20, yield 2.5%
- PEG 2.26 vs DHR's 35.21
- PEG 2.26 vs 4.87
- 27.8% margin vs RAL's -58.6%
HON is the clearest fit if your priority is growth.
- 7.8% revenue growth vs RAL's -4.0%
EMR is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 3.0%, EPS growth 17.8%, 3Y rev CAGR 9.3%
- 216.5% 10Y total return vs DHR's 222.6%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 7.8% revenue growth vs RAL's -4.0% | |
| Value | PEG 2.26 vs 4.87 | |
| Quality / Margins | 27.8% margin vs RAL's -58.6% | |
| Stability / Safety | Beta 0.70 vs RAL's 1.69, lower leverage | |
| Dividends | 2.5% yield, 56-year raise streak, vs DHR's 0.7%, (1 stock pays no dividend) | |
| Momentum (1Y) | +39.5% vs DHR's -11.5% | |
| Efficiency (ROA) | 13.1% ROA vs RAL's -27.7%, ROIC 15.8% vs 6.2% |
RAL vs DHR vs KO vs HON vs EMR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
RAL vs DHR vs KO vs HON vs EMR — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
KO leads in 3 of 6 categories
RAL leads 1 • DHR leads 0 • HON leads 0 • EMR leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
KO leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
KO is the larger business by revenue, generating $49.3B annually — 23.2x RAL's $2.1B. KO is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to RAL's -58.6%. On growth, KO holds the edge at +12.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $2.1B | $24.8B | $49.3B | $36.8B | $18.3B |
| EBITDAEarnings before interest/tax | $371M | $7.2B | $15.5B | $6.5B | $4.7B |
| Net IncomeAfter-tax profit | -$1.2B | $3.7B | $13.7B | $4.1B | $2.4B |
| Free Cash FlowCash after capex | $302M | $5.3B | $12.6B | $4.2B | $3.1B |
| Gross MarginGross profit ÷ Revenue | +46.2% | +60.7% | +61.7% | +36.9% | +52.7% |
| Operating MarginEBIT ÷ Revenue | +11.9% | +21.0% | +29.3% | +14.9% | +19.8% |
| Net MarginNet income ÷ Revenue | -58.6% | +14.9% | +27.8% | +11.2% | +13.3% |
| FCF MarginFCF ÷ Revenue | +14.2% | +21.4% | +25.5% | +11.4% | +17.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +11.0% | +3.7% | +12.1% | -6.9% | +2.9% |
| EPS Growth (YoY)Latest quarter vs prior year | -13.3% | +9.8% | +18.2% | -41.9% | +28.2% |
Valuation Metrics
RAL leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 27.2x trailing earnings, KO trades at a 24% valuation discount to DHR's 35.7x P/E. Adjusting for growth (PEG ratio), KO offers better value at 2.43x vs DHR's 35.21x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $7.4B | $127.5B | $355.6B | $139.6B | $80.1B |
| Enterprise ValueMkt cap + debt − cash | $8.2B | $141.3B | $390.8B | $161.7B | $92.3B |
| Trailing P/EPrice ÷ TTM EPS | -6.13x | 35.73x | 27.18x | 29.93x | 35.41x |
| Forward P/EPrice ÷ next-FY EPS est. | 24.92x | 21.34x | 25.27x | 20.96x | 21.99x |
| PEG RatioP/E ÷ EPS growth rate | — | 35.21x | 2.43x | 16.30x | 7.84x |
| EV / EBITDAEnterprise value multiple | 21.98x | 18.63x | 26.39x | 20.33x | 18.29x |
| Price / SalesMarket cap ÷ Revenue | 3.58x | 5.19x | 7.42x | 3.73x | 4.45x |
| Price / BookPrice ÷ Book value/share | 4.59x | 2.44x | 10.40x | 9.17x | 3.99x |
| Price / FCFMarket cap ÷ FCF | 20.64x | 24.23x | 67.15x | 25.89x | 30.05x |
Profitability & Efficiency
KO leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-52 for RAL. DHR carries lower financial leverage with a 0.35x debt-to-equity ratio, signaling a more conservative balance sheet compared to HON's 2.24x. On the Piotroski fundamental quality scale (0–9), DHR scores 7/9 vs RAL's 3/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -51.7% | +7.1% | +41.1% | +23.1% | +12.1% |
| ROA (TTM)Return on assets | -27.7% | +4.5% | +13.1% | +5.3% | +5.8% |
| ROICReturn on invested capital | +6.2% | +5.9% | +15.8% | +12.6% | +8.2% |
| ROCEReturn on capital employed | +7.6% | +7.0% | +17.3% | +12.6% | +10.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 7 | 7 | 6 | 7 |
| Debt / EquityFinancial leverage | 0.70x | 0.35x | 1.33x | 2.24x | 0.68x |
| Net DebtTotal debt minus cash | $830M | $13.8B | $35.2B | $22.1B | $12.2B |
| Cash & Equiv.Liquid assets | $319M | $4.6B | $10.3B | $12.5B | $1.5B |
| Total DebtShort + long-term debt | $1.1B | $18.4B | $45.5B | $34.6B | $13.8B |
| Interest CoverageEBIT ÷ Interest expense | 5.37x | 18.13x | 10.70x | 3.92x | 6.46x |
Total Returns (Dividends Reinvested)
Evenly matched — RAL and EMR each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KO five years ago would be worth $16,560 today (with dividends reinvested), compared to $8,449 for DHR. Over the past 12 months, RAL leads with a +39.5% total return vs DHR's -11.5%. The 3-year compound annual growth rate (CAGR) favors EMR at 21.1% vs DHR's -4.5% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +29.2% | -21.7% | +20.3% | +13.7% | +6.2% |
| 1-Year ReturnPast 12 months | +39.5% | -11.5% | +17.2% | -0.5% | +14.6% |
| 3-Year ReturnCumulative with dividends | +39.5% | -13.0% | +47.0% | +17.5% | +77.8% |
| 5-Year ReturnCumulative with dividends | +39.5% | -15.5% | +65.6% | +7.9% | +57.7% |
| 10-Year ReturnCumulative with dividends | +39.5% | +222.6% | +121.1% | +135.6% | +216.5% |
| CAGR (3Y)Annualised 3-year return | +11.7% | -4.5% | +13.7% | +5.5% | +21.1% |
Risk & Volatility
Evenly matched — RAL and KO each lead in 1 of 2 comparable metrics.
Risk & Volatility
KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than RAL's 1.69 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RAL currently trades 98.6% from its 52-week high vs DHR's 74.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.69x | 0.70x | -0.20x | 0.84x | 1.61x |
| 52-Week HighHighest price in past year | $67.01 | $242.80 | $84.04 | $248.18 | $165.15 |
| 52-Week LowLowest price in past year | $37.27 | $160.93 | $65.35 | $186.76 | $122.64 |
| % of 52W HighCurrent price vs 52-week peak | +98.6% | +74.2% | +98.3% | +88.8% | +86.6% |
| RSI (14)Momentum oscillator 0–100 | 70.9 | 52.0 | 60.6 | 48.4 | 53.9 |
| Avg Volume (50D)Average daily shares traded | 1.4M | 4.2M | 12.7M | 4.1M | 2.5M |
Analyst Outlook
KO leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: RAL as "Buy", DHR as "Buy", KO as "Buy", HON as "Buy", EMR as "Buy". Consensus price targets imply 28.7% upside for DHR (target: $232) vs -10.5% for RAL (target: $59). For income investors, KO offers the higher dividend yield at 2.46% vs DHR's 0.69%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $59.17 | $231.80 | $86.13 | $250.08 | $163.62 |
| # AnalystsCovering analysts | 7 | 43 | 48 | 28 | 41 |
| Dividend YieldAnnual dividend ÷ price | — | +0.7% | +2.5% | +2.1% | +1.5% |
| Dividend StreakConsecutive years of raises | 1 | 9 | 56 | 8 | 54 |
| Dividend / ShareAnnual DPS | — | $1.23 | $2.04 | $4.63 | $2.10 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +2.4% | +0.2% | +2.7% | +1.6% |
KO leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). RAL leads in 1 (Valuation Metrics). 2 tied.
RAL vs DHR vs KO vs HON vs EMR: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is RAL or DHR or KO or HON or EMR a better buy right now?
For growth investors, Honeywell International Inc.
(HON) is the stronger pick with 7. 8% revenue growth year-over-year, versus -4. 0% for Ralliant Corp. (RAL). The Coca-Cola Company (KO) offers the better valuation at 27. 2x trailing P/E (25. 3x forward), making it the more compelling value choice. Analysts rate Ralliant Corp. (RAL) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — RAL or DHR or KO or HON or EMR?
On trailing P/E, The Coca-Cola Company (KO) is the cheapest at 27.
2x versus Danaher Corporation at 35. 7x. On forward P/E, Honeywell International Inc. is actually cheaper at 21. 0x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: The Coca-Cola Company wins at 2. 26x versus Danaher Corporation's 35. 21x.
03Which is the better long-term investment — RAL or DHR or KO or HON or EMR?
Over the past 5 years, The Coca-Cola Company (KO) delivered a total return of +65.
6%, compared to -15. 5% for Danaher Corporation (DHR). Over 10 years, the gap is even starker: DHR returned +222. 6% versus RAL's +39. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — RAL or DHR or KO or HON or EMR?
By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.
20β versus Ralliant Corp. 's 1. 69β — meaning RAL is approximately -945% more volatile than KO relative to the S&P 500. On balance sheet safety, Danaher Corporation (DHR) carries a lower debt/equity ratio of 35% versus 2% for Honeywell International Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — RAL or DHR or KO or HON or EMR?
By revenue growth (latest reported year), Honeywell International Inc.
(HON) is pulling ahead at 7. 8% versus -4. 0% for Ralliant Corp. (RAL). On earnings-per-share growth, the picture is similar: The Coca-Cola Company grew EPS 23. 6% year-over-year, compared to -502. 2% for Ralliant Corp.. Over a 3-year CAGR, EMR leads at 9. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — RAL or DHR or KO or HON or EMR?
The Coca-Cola Company (KO) is the more profitable company, earning 27.
3% net margin versus -59. 1% for Ralliant Corp. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus 12. 5% for RAL. At the gross margin level — before operating expenses — KO leads at 61. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is RAL or DHR or KO or HON or EMR more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, The Coca-Cola Company (KO) is the more undervalued stock at a PEG of 2. 26x versus Danaher Corporation's 35. 21x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Honeywell International Inc. (HON) trades at 21. 0x forward P/E versus 25. 3x for The Coca-Cola Company — 4. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DHR: 28. 7% to $231. 80.
08Which pays a better dividend — RAL or DHR or KO or HON or EMR?
In this comparison, KO (2.
5% yield), HON (2. 1% yield), EMR (1. 5% yield), DHR (0. 7% yield) pay a dividend. RAL does not pay a meaningful dividend and should not be held primarily for income.
09Is RAL or DHR or KO or HON or EMR better for a retirement portfolio?
For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
20), 2. 5% yield, +121. 1% 10Y return). Ralliant Corp. (RAL) carries a higher beta of 1. 69 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, RAL: +39. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between RAL and DHR and KO and HON and EMR?
These companies operate in different sectors (RAL (Industrials) and DHR (Healthcare) and KO (Consumer Defensive) and HON (Industrials) and EMR (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
DHR, KO, HON, EMR pay a dividend while RAL does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.